Uterine Sarcomas: 10 Years of Experience at a Single Institution

Objective: The present study aims to evaluate the sociodemographic characteristics and clinical management of patients with uterine sarcoma. Methods: Retrospective analysis of 55 patients, who were diagnosed with uterine sarcomas between January 1, 2004–January 1, 2014, was performed. Sociodemographic characteristics, methods used in diagnosis and treatment processes were investigated by accessing the medical files of the patients. All patients were contacted by telephone to obtain information about disease progression and recurrence. Patients’ death reports were obtained from the national database of the Ministry of Health and the findings were analyzed statistically. Results: In this study, 55 cases of uterine sarcoma, of whom 31 carcinosarcomas (56.4%), 15 leiomyosarcomas (27.3%), six endometrial stromal sarcomas (10.9%) and three adenosarcomas (5.5%) were analyzed. The median age was 60.75±12.74 (min-max: 33–86). Fortythree (78.2%) patients were in postmenopausal period. Twenty-seven (47.3%) of these patients were diagnosed by endometrial sampling, 17 (30.9%) patients were diagnosed by frozen section, 11 (20%) patients were diagnosed by hysterectomy and one (1.81%) patient was diagnosed by myomectomy. Three patients had distant metastases at the time of diagnosis. According to FIGO (International Federation of Gynecology and Obstetrics) 2009, 65.5% of the patients were diagnosed at stage 1. 58.5% of the patients who underwent surgery were operated by gynecologist-oncologist. Total abdominal hysterectomy with bilateral salping-oopherectomy was performed in 52 patients (94.5%). Pelvic lymph node dissection was performed in 28 patients (51%). The mean survival time was 47 months in carcinosarcoma, 49.6 months in leiomyosarcoma, 84.8 months in endometrial stromal sarcoma and 68.7 months in adenosarcoma. Until the last date of collecting data, January 2019, 37 patients (67.3%) died. Conclusion: Uterine sarcomas are rare tumors with poor prognosis even in the early stages. Each histological type should be evaluated separately. Surgery is the main treatment method in uterine sarcoma. The role of adjuvant therapy is controversial.

Uterin Sarkomlar: Tek Merkezin 10 Yıllık Deneyimi

Amaç: Bu çalışmadaki amaç, uterin sarkom tanısı alan hastaların sosyodemografik özelliklerini ve bu hastalara klinik yaklaşımı değerlendirmektir. Gereç ve Yöntem: Bu çalışmada Kadın Hastalıkları ve Doğum Kliniğimizde 1 Ocak 2004–1 Ocak 2014 tarihleri arasında uterin sarkom tanısı alan 55 hasta geriye dönük olarak irdelendi. Hastaların tıbbi dosyalarına ulaşılarak sosyodemografik veriler, hastalığın tanı ve tedavi süreçlerinde uygulanan yöntemler araştırıldı. Hastalar telefonla aranarak hastalığın progresyonu ve rekürrens ile ilgili bilgilerine ulaşıldı. Sağlık bakanlığı hasta ölüm bildirim raporlarına ulaşılarak hasta ölüm tarihleri belirlendi ve bulgular istatiksel olarak analiz edildi. Bulgular: Otuz bir karsinosarkom (%56.4), 15 leiomyosarkom (%27.3), altı endometrial stromal sarkom (%11), üç adenosarkom (%5.5) olmak üzere toplam 55 uterin sarkom tanılı hasta değerlendirmeye alındı. Ortalama yaş 60.75±12.74 (yaş aralığı 33–86) idi. Kırk üç hasta (%78.2) postmenopozal dönemde idi. Yirmi altı hasta (%47.3) endometrial örnekleme, 17 hasta (%31) frozen patolojik inceleme, 11 hasta abdominal histerektomi (%20) ve bir hasta abdominal miyomektomi (%1.8) tanısı aldı. Tanı anında üç hastada uzak metastaz saptandı. FIGO 2009’a göre evrelenen hastaların %65.5’inin evre-1 olduğu saptandı. Cerrahi operasyona giden hastaların %58.5’i jinekolog-onkolog tarafından ameliyat edildi. Elli iki hasta (%94.5) total abdominal histerektomi ve iki taraflı salpingooferektomi oldu. Yirmi sekiz hastaya (%51) pelvik lenf nodu disseksiyonu yapıldı. Ortalama sağkalım süresi karsinosarkomda 47 ay, leiomyosarkomda 49.6 ay, endometrial stromal sarkomda 84.8 ay, adenosarkomda 68.7 ay olarak hesaplandı. Verilerin toplandığı ocak 2019 tarihine kadar 37 hasta (%67.3) hayatını kaybetti. Sonuç: Uterus sarkomları nadir izlenen, erken evrede bile prognozu kötü olan tümörlerdir. Her bir histolojik tip ayrı ayrı değerlendirilmelidir. Uterus sarkomlarında temel tedavi cerrahi olarak kabul görmüştür. Adjuvan tedavilerin rolü tartışmalıdır.

Kaynakça

1. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, et al. Prognostic factors in early-stage uterine sarcoma. Cancer 1993;71:1702–9.

2. Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54:355–64.

3. D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010;116:131–9.

4. Nucci MR. Practical issues related to uterine pathology: endometrial stromal tumors. Mod Pathol 2016;29:S92–103.

5. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687–90.

6. Fletcher CD. The evolving classification of soft tissue tumours–an update based on the new 2013 WHO classification. Histopathology 2014;64:2–11.

7. Tropé CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol 2012;51:694–705.

8. Giuntoli RL 2nd, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003;89:460–9.

9. Chang KL, Crabtree GS, Lim-Tan SK, Kempson RL, Hendrickson MR. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol 1990;14:415–38.

10. Menczer J, Schreiber L, Berger E, Ben-Shem E, Golan A, Levy T. CA125 expression in the tissue of uterine leiomyosarcoma. Isr Med Assoc J 2014;16:697–9.

11. Bansal N, Herzog TJ, Burke W, Cohen CJ, Wright JD. The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol 2008;110:43–8.

12. Skorstad M, Kent A, Lieng M. Preoperative evaluation in women with uterine leiomyosarcoma. A nationwide cohort study. Acta Obstet Gynecol Scand 2016;95:1228–34.

13. Quinlivan JA, Petersen RW, Nicklin JL. Accuracy of frozen section for the operative management of endometrial cancer. BJOG 2001;108:798–803.

14. El-Bahrawy M, Ganesan R. Frozen section in gynaecology: uses and limitations. Arch Gynecol Obstet 2014;289:1165–70.

15. Bostancı E, Ayas S, Gürbüz T, Gürbüz A, Karateke A. Retrospective analysis of 29 cases with uterine sarcoma: A single center experience. Dicle Med J 2015;42:175–80.

16. Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009;104:177–8.

17. Pellanda AF, De Bari B, Deniaud-Alexandre E, Krengli M, Van Houtte P, Richetti A, et al. Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study. Chin J Cancer Res 2017;29:521–32.

18. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol 1990;21:363–81.

19. Carleton C, Houghton OP, McCluggage WG. Juvenile granulosa cell tumor arising in ovarian adenosarcoma: an unusual form of sarcomatous overgrowth. Hum Pathol 2015;46:614–9.

20. Bernard B, Clarke BA, Malowany JI, McAlpine J, Lee CH, Atenafu EG, et al. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival. Gynecol Oncol 2013;131:634–9.

21. Verschraegen CF, Vasuratna A, Edwards C, Freedman R, Kudelka AP, Tornos C, et al. Clinicopathologic analysis of Mullerian adenosarcoma: the M.D. Anderson Cancer Center experience. Oncol Rep 1998;5:939–44.

22. D’Angelo E, Espinosa I, Ali R, Gilks CB, van de Rijn M, Lee CH, et al. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol 2011;121:328–33.

23. Agarwal R, Rajanbabu A, Nair IR, Satish C, Jose G, Unikrishnan UG. Endometrial stromal sarcoma-A retropsective analysis of factors affecting recurrence. Eur J Obstet Gynecol Reprod Biol 2017;216:92–7.

24. Tanner EJ, Garg K, Leitao MM Jr, Soslow RA, Hensley ML. High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol 2012;127:27–31.

25. Lee CH, Mariño-Enriquez A, Ou W, Zhu M, Ali RH, Chiang S, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 2012;36:641–53.

26. Seagle BL, Shilpi A, Buchanan S, Goodman C, Shahabi S. Low-grade and high-grade endometrial stromal sarcoma: A National Cancer Database study. Gynecol Oncol 2017;146:254–62.

27. Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, et al. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. Gynecol Oncol 2003;90:529–36.

28. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 2007;31:1653–61.

29. Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000;88:2782–6.

30. Tavassoli FA, Devilee P, editors. Pathology and Genetics: Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours. Lyon: IARC; 2003.

31. Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:526–31.

32. Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1–19.

33. George E, Lillemoe TJ, Twiggs LB, Perrone T. Malignant mixed müllerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 1995;14:39–44.

34. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 2008;112:820–30.

35. Bogani G, Fucà G, Maltese G, Ditto A, Martinelli F, Signorelli M, et al. Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis. Gynecol Oncol 2016;143:443–7.

36. Benson C, Miah AB. Uterine sarcoma–current perspectives. Int J Womens Health 2017;9:597–606.

37. Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol 2012;30:850–6.

38. Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic softtissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017;18:1397–410.

Kaynak Göster

Southern Clinics of Istanbul Eurasia
  • ISSN: 2587-0998
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 2017

662118

Sayıdaki Diğer Makaleler

Cortisol as a Predictor of Early Mortality in Heart Failure

Mehmet YAMAK, Hatice TÜKENMEZ, Meltem SERTBAŞ, Mehmet Akif TÜKENMEZ, Süleyman AHBAB, Hayriye Esra ATAOĞLU

Ochronotic Arthropathy: A Report of Two Cases

Selma ŞENGİZ ERHAN, Sevinç HALLAÇ KESER, Kubilay GÜLSEVER, Sibel SENSU

Management of Femoral Fractures in Aging Adult Polio Population: A Retrospective Review of 13 Cases

Hüseyin Bilgehan ÇEVİK, Engin ECEVİZ, Selim ERGÜN, Seyit Ali GÜMÜŞTAŞ

Who should Perform the Asthma Control Test: Patient? Physician?

Seda Beyhan SAĞMEN, Sevda Şener CÖMERT, Coşkun DOĞAN, Elif TORUN PARMAKSIZ, Ali Fidan FİDAN, Banu SALEPCİ MUSAFFA, Nesrin KIRAL

Does Abnormal Uterine Bleeding in Menstrual Cycles Predispose Postpartum Bleeding? A Prospective Study

Ali DOĞUKAN ANĞIN, Kazibe KOYUNCU, İsmet GÜN, Lokman Tekin ERTEKİN, Önder SAKİN, Emine Eda AKALIN, Muzaffer Seyhan ÇIKMAN, Ahmet KALE, Engin Ersin ŞİMŞEK

Macular Electrophysiology After Intravitreal Dexamethasone Implant in Patients with Branch Retinal Vein Occlusion

Muhammed Nurullah BULUT, Ümit ÇALLI, Ulviye KIVRAK, Kezban BULUT, Güzide AKÇAY

Postoperative Analgesia after Cardiac Surgery: Is there a Safe Alternative to Opioids?

Vedat ELJECİ

Preoperative Airway Management Checklist: The Transfer of Knowledge Into Clinical Practice by Video-based Feedback

Tahsin ŞİMŞEK, Mehmet Birhan YILMAZ, Ayten SARAÇOĞLU, Kemal Tolga SARAÇOĞLU

Spinal Infarction Following Myocardial Infarction: A Case Report

Avni Uygar SEYHAN, Semih KORKUT, Ahmet Erdal YILMAZ, Nurhayat BAŞKAYA, Nihat Müjdat HÖKENEK, Hatice Kübra ÖNDER KARAGÖZ, Nefise ÇELİK

Reporting Complications in Radical Cystoprostatectomy and Orthotopic Neobladder in Male Patients Using a Standard Reporting Methodology

Orkunt ÖZKAPTAN, Alkan ÇUBUK, Muhsin BALABAN, Cüneyd SEVİNÇ, Osman Murat İPEK, Tahir KARADENİZ